These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28007775)

  • 1. Beating the Clock in T-cell Acute Lymphoblastic Leukemia.
    Carroll WL; Aifantis I; Raetz E
    Clin Cancer Res; 2017 Feb; 23(4):873-875. PubMed ID: 28007775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.
    Pikman Y; Alexe G; Roti G; Conway AS; Furman A; Lee ES; Place AE; Kim S; Saran C; Modiste R; Weinstock DM; Harris M; Kung AL; Silverman LB; Stegmaier K
    Clin Cancer Res; 2017 Feb; 23(4):1012-1024. PubMed ID: 28151717
    [No Abstract]   [Full Text] [Related]  

  • 3. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
    Schult C; Dahlhaus M; Glass A; Fischer K; Lange S; Freund M; Junghanss C
    Anticancer Res; 2012 Feb; 32(2):463-74. PubMed ID: 22287733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells.
    Silic-Benussi M; Sharova E; Ciccarese F; Cavallari I; Raimondi V; Urso L; Corradin A; Kotler H; Scattolin G; Buldini B; Francescato S; Basso G; Minuzzo SA; Indraccolo S; D'Agostino DM; Ciminale V
    Redox Biol; 2022 May; 51():102268. PubMed ID: 35248829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
    Gazi M; Moharram SA; Marhäll A; Kazi JU
    Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Daver N; Boumber Y; Kantarjian H; Ravandi F; Cortes J; Rytting ME; Kawedia JD; Basnett J; Culotta KS; Zeng Z; Lu H; Richie MA; Garris R; Xiao L; Liu W; Baggerly KA; Jabbour E; O'Brien S; Burger J; Bendall LJ; Thomas D; Konopleva M
    Clin Cancer Res; 2015 Jun; 21(12):2704-14. PubMed ID: 25724525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.
    Simioni C; Martelli AM; Zauli G; Vitale M; McCubrey JA; Capitani S; Neri LM
    J Cell Physiol; 2018 Oct; 233(10):6440-6454. PubMed ID: 29667769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
    Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
    Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
    Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
    Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.
    Lim JT; Singh N; Leuvano LA; Calvert VS; Petricoin EF; Teachey DT; Lock RB; Padi M; Kraft AS; Padi SKR
    Mol Cancer Ther; 2020 Sep; 19(9):1809-1821. PubMed ID: 32753387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
    Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.
    Martelli AM; Lonetti A; Buontempo F; Ricci F; Tazzari PL; Evangelisti C; Bressanin D; Cappellini A; Orsini E; Chiarini F
    Adv Biol Regul; 2014 Sep; 56():6-21. PubMed ID: 24819383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia.
    Bride KL; Hu H; Tikhonova A; Fuller TJ; Vincent TL; Shraim R; Li MM; Carroll WL; Raetz EA; Aifantis I; Teachey DT
    Haematologica; 2022 Aug; 107(8):1746-1757. PubMed ID: 34937317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
    Yang X; He G; Gong Y; Zheng B; Shi F; Shi R; Yang X
    Eur J Haematol; 2014 Feb; 92(2):111-20. PubMed ID: 24112092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update.
    Evangelisti C; Chiarini F; McCubrey JA; Martelli AM
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29949919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
    Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
    Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.
    Nowak D; Liem NL; Mossner M; Klaumünzer M; Papa RA; Nowak V; Jann JC; Akagi T; Kawamata N; Okamoto R; Thoennissen NH; Kato M; Sanada M; Hofmann WK; Ogawa S; Marshall GM; Lock RB; Koeffler HP
    Exp Hematol; 2015 Jan; 43(1):32-43.e1-35. PubMed ID: 25450514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic targeting of CHK1 and mTOR in MYC-driven tumors.
    Song X; Wang L; Wang T; Hu J; Wang J; Tu R; Su H; Jiang J; Qing G; Liu H
    Carcinogenesis; 2021 Apr; 42(3):448-460. PubMed ID: 33206174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.